Interferon-oc (IFN-oc) has been widely used for treatment of chronic hepatitis C in Japan. In general, cardiovascular adverse reactions are rare in association with IFN-oc therapy. Here, a 64-year-old man with chronic active hepatitis C complained of fatigue, palpitation and depression, and developed atrial fibrillation with prominent negative T waves during IFN-oc therapy. Echocardiogram showed septal and apical hypertrophy. Three days after discontinuation of IFN-oc, subjective symptomsand atrial fibrillation subsided. It is unclear whether or not IFN-ainducedthe giant negative T waves with apical hypertrophy. Wemight observe the developing course of hepatitis C virus (HCV) -related myocardial hypertrophy by chance. Cardiovascular toxicity should be carefully monitored during IFN-a therapy even in patients with minor cardiac disease, such as premature ventricular contracture (PVC) and mild hypertension. (Internal Medicine 40: 105-109, 2001) 
Introduction
Interferon (IFN) is the widely used for the treatment of hematological malignancies and chronic hepatitis. Virtually, all patients experience some toxicity during the therapy. Primarily, this involves flu-like symptomssuch as fever, chills and malaise (1) . However, transient leukopenia, asymptomatic increase in hepatic transaminase levels, somnolence, confusion and rash mayoccur. Cardiovascular toxicity related to IFN therapy, including hypotension and tachycardia, has been noted infrequently ranging from less than 5 to 12 percent (2). Generally, IFN-associated cardiovascular toxicity is considered to be very rare in the treatment of chronic viral hepatitis (3) . We describe a patient with chronic active hepatitis C whowas treated with IFN-a2 and subsequently experienced supraventricular premature beats and atrial fibrillation with giant negative T waves.
For editorial comment, see p 78.
Case Report
A 64-year-old man was admitted to our hospital for treatment of chronic active hepatitis C on February 7, 1997. He had a past medical history of acute hepatitis in 1955, premature ventricular contracture (PVC), duodenal ulcer and mild hypertension since 1984. Thus, nicardipine and captopril have been administered for 12 years. On admission, his body temperature was 36.1°C, height 165 cm, weight 74 kg, and a body mass index 27.2 kg/m2. On physical examination, the patient was alert and normotensive (1 20/68 mmHg)with a regular pulse rate (76/min), and heart murmurwas not audible. The liver was palpable 3 cm beneath the right costal margin, dull edged and smoothly surfaced, vascular spider and palmar erythema were not observed. Neither systemic nor local edemawas present. Laboratory findings were as follows: a hemoglobin concentration was 15.0 g/dl, a white blood cell count 6.0x103/ jllI, and a platelet count 152xlO3 /|Lil. Serum levels of aspartate aminotransferase (8 1 IU//; normal range, 1 1-32 IU//), alanine aminotransferase (99 IU//; normal range, 6-39 IU//) and lactate dehydrogenase (490 IU//; normal range, 236-455 IU//) were modestly increased. Serum anti-hepatitis C virus (HCV) antibody (the 2nd generation, PHA method) was positive. Serum HCV-RNAwas 0.56 MEQ/ml. HCVgenotype (international classification) was 2b. On February 12, an electrocardiogram (ECG) tracing showed a regular rhythm left ventricular hypertrophy with a mild ST-T change (Fig. 1A) . A chest radiograph revealed mild cardiomegaly, and the cardiothoracic ratio was 52.0%. Ultrasonic cardiography (UCG) findings were compatible to hypertensive heart (mild left ventricle hypertrophy, interventricular septal wall thickness at the mid portion, IVST: 12 mm, left ventricular posterior wall thickness, LVPWT: 12 mm)( Fig. 2A) . At that time, apex was not carefully examined for hypertrophy. Abdominal echogram did not show a cirrhotic pattern. Based on the low HCV-RNAlevel, good prognosis genotype, and a chronic hepatitis pattern in the abdominal ultrasonography, diagnostic laparoscopy was performed to determine the clinical indication of IFN therapy. The liver specimen was histologically diagnosed as chronic active hepatitis. As shown in Fig. 3 , IFN therapy was started on March 10, 1997; IFN-cc2b (Intron A, Schering-Plough, 10 million unit/ day) was injected intramuscularly for nine days. In the first 4 days, he developed a high fever, but the fever subsided gradually thereafter. On March 17 (7th day of administration of IFNa), ECGduring a regular check-up had already shown supraventicular premature beats with giant negative T waves (Fig. IB) . On March 19 (10th day of administration of IFN-oc), the patient complained of fatigue, palpitation and depressive feeling. Serumlevels of creatinine phosphokinase were within a normal limit. ECGshowed tachycardia (100 beats per minutes) and supraventicular premature beats with giant negative T waves, and then atrial fibrillation emerged. UCGrevealed septal and apical hypertrophy (IVST: 17 mm, LVPWT: 12 mm). The IFN therapy was discontinued. On the same day, the patient received digoxin 0.25 mg i.v., and from the next day, methyldigoxin 0.1 mg/day was administered. On March 21 (2 days after the cessation of the IFN therapy), ECGshowed atrial fibrillation with giant negative T waves (Fig. 1C) . On March 24 (4 days after the cessation of the IFN therapy), subjective symptoms improved and atrial fibrillation disappeared. On (Fig* IE) . On January 19, 2000, UCGclearly revealed apical hypertrophy (apical twochamber view, C).
Discussion
Therehave beenseveral reports documentingatrial fibrillation during or after IFNtherapy. Mostof themwerefrompatients with malignancies,whowereheavily treated with anticancer agents or had ischemic heart disease (4). Despite the conventional use of IFN-oc, only 7 out of ll,241 (0.06%) patients with chronic hepatitis have reportedly developedcardiovascular complications (3, 5) . Althoughcardiovascular complications are consideredto be veryrare in patients withchronic hepatitis as compared withthose withmalignant diseasesreceiving intensive chemotherapy, Teragawaet al have reported 6 patients with cardiovascular adverse effects during interferon therapy and 4 morepatients within 1 year after the end of therapy (10/3 12, 3.2%), including arrhythmia (n = 4), ischemic heart disease (n = 4) and myocardial disease (n = 2) (6). Furthermore, Torsades de Pointes (7), non-sustained ventricular tachycardia (8) , cardiogenic shock (9) and sinus bradycardia ( 10) werereported during IFN-octherapy for chronic hepatitis C Accordingly,IFN-associated cardiovascular toxicity in the treatmentof chronichepatitis Cmightbe morecommon than previouslyexpected. Interestingly, two reported cases (7, 8 ) and the present case had the samepast history of PVCand mild hypertension controlled by anti-hypertensive drugs. High age, taking anti-hypertensive drugs and transient PVCmayinducecardiac complications whenIFNtherapy is added. Careful cardiac monitoring shouldbe requiredin these patients. Matsumoriet al have intensively reported that HCVinfection maycontribute to the developmentof cardiomyopathy( 1 1-13). Recently, Matsumori et al have reported that 6 out of 9 HCV patients with hypertrophic cardiomyopathyshowedaceof-spades-shaped deformitiesof the left ventricle with apical hypertrophy (14) . However,these reports fromJapan are in disagreement with those from Greece, Germanyand Italy (15) (16) (17) . Dalekoset al havenot indicated a pathogeniclink between HCVinfection and cardiomyopathy (15) . They have speculated that geneticor other factors couldbe the reasonfor this discrepancy. Therelationship betweenHCV infection and cardiomyopathy is still controversial. Furthermore,noreports have discussed a history of IFNtherapy. It is importantto contemplatewhatfactor inducedthe giant negative T wavesduring only four weeksin this case. First, we observed that myocardial hypertrophy induced by HCVhad just begun incidentally. Second, IFNwith or without anti-hypertensive drugs (captoril andnicardipine) inducedmyocardial hypertrophy. Whenthe giant negative T wavesemerged, symptoms of infection werenot observed.At this time, wedid not use additional treatment except for IFN, and hadto discontinue it becauseof adverse reactions. AlthoughIFN-induced myocardial hypertrophy in experimental modelshave not been reported, Omae et al havereportedseptal/left ventricle posterior wall hypertrophy9 daysafter the start of treatmentof IFN, but they did not discuss the previous status (8) . In summary, wereporteda rare casein whichgiant negative T wavesand atrial fibrillation developedduring IFNtherapy for chronic hepatitis C. CoincidentalHCV-induced or IFN-inducedapical hypertrophy wasspeculated. Careful cardiac monitoringis required in patients with trivial cardiac medical history, such as PVCor hypertension during the IFNtherapy.
